Christopher Selby is a pharmacist who is specialized in Oncology in Dallas, Texas. Patients can reach him at 5920 Forest Park Rd Ste 523, Dallas or contact him on 214-358-9071. Active license number of Christopher Selby is 62383 for Oncology in Texas. Christopher Selby is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Christopher Selby speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Christopher Selby
Specialization:
Oncology
Credentials:
PHARMD, BCOP
Gender:
Male
Location:
5920 Forest Park Rd Ste 523, Dallas, Texas, 75235-6411
Phone:
214-358-9071
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Christopher Selby are as mentioned below.
NPI Number:
1093606907
NPI Enumeration Date:
10 Jul, 2025
NPI Last Update On:
10 Jul, 2025
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Christopher Selby are as mentioned below.
Specialization
License Number
State
Status
Oncology
62383
Texas
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
5920 Forest Park Rd Ste 523, Dallas, Texas
Zip:
75235-6411
Phone Number:
214-358-9071
Fax Number:
--
Patients can reach Christopher Selby at 5920 Forest Park Rd Ste 523, Dallas, Texas or can call on phone at 214-358-9071.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 October, 2025.